|
Exports of bulk drugs and intermediates reported a growth of 8.33% in the first half of the current fiscal year on a YoY basis, reporting a trade surplus of almost $229 million for the period.
Exports during the second quarter of the fiscal year grew 10%, while for the month of September, 2025, there was a growth of 5.74%, according to data from the ministry of commerce and industry.
The bulk drugs and intermediates exports during the six months from April to September, 2025 stood at $2.47 billion, as against $2.28 billion in the same period of last year. Quantity of exports grew 12.40% to 2,41,928 MT as against 2,15,255 MT during the comparable period.
In Rupee terms, the growth was almost 12% at Rs. 21,325.3 crore during the six months ended September 30, 2025, as compared to Rs. 19,096 crore during the same period of last year.
As reported earlier, imports of bulk drugs and intermediates to India has reported a decline of 2.6% in the first half of the fiscal year 2025-26, as compared to a growth of 3.13% reported in the same period of previous fiscal year, on a year-over-year (YoY) basis. During the month of September, the imports grew 1.5%, as against the same month last year.
During the quarter from July to September, 2025, exports grew 10% to $1.27 billion on a YoY basis, compared to $1.15 billion. Quantity of exports grew 16% to 1,21,732 MT compared to 1,04,866 MT during the same quarter a year ago.
In Rupee terms, the growth was 14.77% during the quarter, at Rs. 11,073.8 crore as against Rs. 9648.28 crore reported in the second quarter of last fiscal year.
Exports during the month of September, 2025 was at $444.30 million compared to $420.16 million during the same month of last year. Quantity of exports grew 12% to 36,949.8 MT as against 32,968.4 MT on a YoY basis.
In Rupee terms, the growth was 11.44% to Rs. 3,924.2 crore compared to Rs. 3521.26 crore reported in September, 2024.
As reported earlier, the exports during the financial year ended March, 2025 reported a 2.3% growth to $4.9 billion, as compared to $4.79 billion in the previous fiscal year. Quantity, on the other hand, declined 3.2% to 4,59,449 MT as compared to 4,74,617 MT reported during April, 2023 to March, 2024.
The Central government has been emphasising on reducing the imports of essential pharmaceutical raw materials such as bulk drugs, drug intermediates and key starting materials, among others, and has initiated various incentive schemes to support domestic production of these materials.
The Department of Pharmaceuticals has been promoting production of pharma raw materials in the country, including through a production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (KSMs)/drug intermediates and active pharmaceutical ingredients (APIs) in the country, to support the industry in various aspects regarding ease of doing business and availing the benefits of the Scheme.
It has also announced schemes to promote bulk drug parks in the country, as part of its efforts to promote domestic manufacturing of pharma ingredients.
|